These findings shed light on the potential of semaglutide to mitigate the chronic sequelae of diabetes-related foot ulcers, offering hope for improved long-term patient outcomes
These drugs mimic the action of a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels by enhancing insulin production and reducing the amount of glucose produced by the liver, potentially helpful in addressing blood sugar, particularly in patients with Type 2 Diabetes
[15] [16] Gastrointestinal symptoms may be misattributed to fatigue or may coexist with and contribute to tiredness
Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study
Semaglutide is an incretin mimetic
A s much as 12 percent of American adults are now using GLP-1 medications, with US patients spending US$40 billion on appetite-suppressing drugs in 2024